FDA approves darolutamide for non-metastatic castration-resistant prostate cancer

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer On July 30 2019 the Food and Drug Administration approved darolutamide NUBEQA Bayer HealthCare Pharmaceuticals Inc for non-metastatic castration-resistant prostate cancer Ap [...]